Sol-Gel Technologies’ work to expand the treatment options for patients with the skin condition rosacea has paid off, with the FDA approving a product based on its microencapsulation technology.
Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for Gorlin syndrome and extending cash runway to 2027. Sol-Gel Technologies, Ltd. has announced a product purchase ...
Dublin, April 07, 2025 (GLOBE NEWSWIRE) -- The "The Global Sol-Gel Coatings Market 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Global Sol-Gel Coatings Market 2025-2035 ...
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), is pleased to announce that it ...
PreveCeutical Medical (OTCQB:PRVCF) said it granted Endosane Pharmaceuticals an option to license sol-gel technology for the delivery of cannabinoid products on an exclusive basis. The purpose of the ...
The University of Queensland has struck a deal with Canadian health and wellness company PreveCeutical Medical which could revolutionize the way patients take medical cannabis. Invented at the UQ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback